Vascular dementia refers to the decline in cognitive functioning following reduced blood flow to different parts of the brain. It is associated with cerebrovascular disease that damages brain cells.

The global vascular dementia treatment market is estimated to be valued at US$ 3.10 Bn in 2024 and is expected to exhibit a CAGR of 4.1% over the forecast period of 2024-2031.

Some key advantages of vascular dementia drugs are that they can help improve symptoms, slow progression, prevent further damage to blood vessels in the brain and lower the risk of additional strokes. The growing geriatric population suffering from cardiovascular diseases and strokes has increased the prevalence of vascular dementia globally, driving the need for effective treatment options.

Key Takeaways

Key players operating in the vascular dementia market are CSPC Ouyi Pharmaceutical, Aptinyx, Oryzon Genomics, Lundbeck, Novartis. CSPC Ouyi Pharmaceutical is one of the leading players in the vascular dementia market with its product Ginkgo Biloba tablets. Key opportunities in the market include raising awareness about vascular dementia to reduce stigma and increase early diagnosis. Companies are also exploring opportunities for drug repurposing and new molecular entities to target underlying causes and have disease-modifying effects. Globally, players are expanding into emerging markets of Asia Pacific and Latin America through partnerships and acquisitions to tap into the growing patient pools in these regions.

Market drivers: The growing geriatric population is a key driver of the vascular dementia market. As per the United Nations, the number of people aged 65 years and above is projected to reach 1.5 billion by 2050. Old age is the strongest risk factor for vascular dementia. Other driver includes increasing incidence of cerebrovascular diseases like stroke which can lead to vascular dementia.

Market restraints: High attrition rates during clinical trials of novel drug candidates and lack of approved disease-modifying drugs are key restraints. Most drugs currently available only manage symptoms and do not alter disease progression. Difficulties in early diagnosis of vascular dementia is also a challenge as symptoms often overlap with Alzheimer's disease. Lack of biomarkers for differential diagnosis hinders timely intervention and management.
Segment Analysis

The vascular dementia market can be segmented based on drugs class and distribution channel. Based on drugs class, the cholinesterase inhibitors segment holds the largest market share as these are the first line of treatment for vascular dementia. Drugs like donepezil, rivastigmine, galantamine are the commonly used cholinesterase inhibitors prescribed by physicians for mild to moderate vascular dementia patients. The memantine segment is expected to witness high growth during the forecast period as these drugs are effective for moderate to severe stages of vascular dementia.

Based on the distribution channel, the hospital pharmacies segment dominates the market due to the availability of a wide range of dementia drugs and patients preferring hospitals for immediate treatment. The retails pharmacies segment will grow substantially in developing regions due to increasing healthcare awareness and easy accessibility however lack of effective reimbursement policies can hamper its growth. The online pharmacies segment will show lucrative growth owing to the ease of purchase and home delivery of drugs.

Global Analysis

The North American region accounts for the largest share in the global vascular dementia market due to the rising geriatric population, existence of well-established healthcare infrastructure and high healthcare spending. Europe is the second largest market due to the growing prevalence of vascular dementia. The Asia Pacific region will exhibit the fastest growth rate during the forecast period due to increasing healthcare expenditure, large patient population and raising government initiatives to spread awareness regarding dementia. Considerable growth will also be witnessed in Latin American and Middle East & African countries due to improving economic conditions.

Get more insights on this topic : https://justpaste.it/cekcm

What Are The Key Data Covered In This Vascular Dementia Market Report?

:- Market CAGR throughout the predicted period

:- Comprehensive information on the aspects that will drive the Vascular Dementia 's growth between 2024 and 2031.

:- Accurate calculation of the size of the Vascular Dementia  and its contribution to the market, with emphasis on the parent market

:- Realistic forecasts of future trends and changes in consumer behaviour

:- Vascular Dementia  Industry Growth in North America, APAC, Europe, South America, the Middle East, and Africa

:- A complete examination of the market's competitive landscape, as well as extensive information on vendors

:- Detailed examination of the factors that will impede the expansion of Vascular Dementia  vendors

About Author:

Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. (https://www.linkedin.com/in/ravina-pandya-1a3984191)

*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it